Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Seliciclib (Roscovitine) 是 Cdk2/cyclin E 的有效抑制剂,IC50为0.1 µM。它还抑制 Cdk7/cyclin H、Cdk5/p35 和 Cdc2/cyclin B,IC50为 0.49、0.16和0.65 µM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 415 | 现货 | ||
10 mg | ¥ 734 | 现货 | ||
25 mg | ¥ 995 | 现货 | ||
50 mg | ¥ 1,597 | 现货 | ||
100 mg | ¥ 2,433 | 现货 | ||
200 mg | ¥ 3,996 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 457 | 现货 |
产品描述 | Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM). |
靶点活性 | CDK5-p35:0.16 μM (cell free), ERK2:14 μM (cell free), CDK2-CyclinE:0.7 μM (cell free), CDC2-cyclinB:0.65 μM (cell free), CDK2-CyclinA:0.7 μM (cell free) |
体外活性 | Most kinases are not significantly inhibited by roscovitine. cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 only are substantially inhibited (IC50 values of 0.65, 0.7, 0.7 and 0.2 μM, respectively). Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 microM and 14 microM, respectively. Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late prophase [1]. Roscovitine (25 microM) inhibited FCS-induced proliferation in cultured MC [2]. |
体内活性 | In diabetic rats, CDK5 inhibitor roscovitine decreased renal fibrosis and improved renal function [3]. In vivo experiments showed that s.c. growth of ESFT xenografts was also significantly slowed by i.p. injection of roscovitine [4]. |
激酶实验 | Kinases activities were assayed at 30°C in buffer C (unless otherwise specified). Blank values were substracted from the data and activities calculated as the molar amount of phosphate incorporated in protein acceptor during a 10-min incubation. Controls were performed with appropriate dilutions of Me2SO. In a few cases, phosphorylation of the substrate was assessed by autoradiography after SDS/PAGE [1]. |
细胞实验 | L1210 cells taken from exponentially growing cultures in RPMT-1640 medium supplemented with 10% foetal calf serum, penicillin and streptomycin, were counted using a hemocytometer, seeded at 5X10^4 cells/ml in tissue-culture 96-wells plates in the presence or absence of various concentrations of roscovitine or olomoucine and incubated at 37°C under 5% CO,. For reversion of the roscovitine effect, L1210 cells cultured two days in the presence or absence of roscovitine were washed in phosphate-buffered saline to remove any trace of the drug, counted and reseeded in fresh medium containing no drug. Cell growth was monitored daily using the microculture tetrazolium assay. Cell cycle analysis was performed on cells that were fixed in ethanol, treated with 100 μg/ml RNase and stained with propidium iodide. We used a Coulter EPICS Elite flow cytometer for acquisition and the Multicycle software for analysis of the data. All assays were performed in triplicate and experiments repeated at least twice [1]. |
动物实验 | Male athymic nude mice (5-6 weeks old) were obtained from the National Cancer Institute. Mice were housed in the animal facilities of the Georgetown University Division of Comparative Medicine. All animal work was done under protocols approved by the Georgetown University Animal Care and Use Committee. Mice were inoculated s.c. into the right posterior flank with 4 × 10^6 A4573 cells in 100 μL of Matrigel basement membrane matrix. Xenografts were grown to a mean tumor volume of 129 ± 30 mm^3. Roscovitine was first dissolved in either absolute methanol or DMSO (1 volume). A carrier solution was produced by using a diluent containing 10% Tween 80, 20% N-N-dimethylacetamide, and 70% polyethylene glycol 400. Mice were randomized into two groups (six animals per group) and treatment was initiated. One group was treated with roscovitine, administered as a single daily i.p. injection, at a dose of 50 mg/kg, for either 5 days or two 5-day series with a 2-day break in between. The control group received i.p. injections of the carrier solution following identical schedules. All mice were sacrificed by asphyxiation with CO2. Roscovitine-treated mice were euthanized either 7 days after the first injection or up to 4 weeks after completion of the treatment. At those times, tumors were removed, measured, and prepared for TUNEL assays. Primary tumor volumes were calculated by the formula V = (1/2)a × b2, where a is the longest tumor axis and b is the shortest tumor axis. Data are given as mean values ± SE in quantitative experiments. Statistical analysis of differences between groups was done by a one-way ANOVA followed by an unpaired Student's t-test [4]. |
别名 | Roscovitine, R-roscovitine, CYC202 |
分子量 | 354.45 |
分子式 | C19H26N6O |
CAS No. | 186692-46-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 50 mg/mL (141.06 mM)
Ethanol: 6 mg/mL (16.92 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.8213 mL | 14.1064 mL | 28.2127 mL | 70.5318 mL |
5 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | 14.1064 mL | |
10 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL | 7.0532 mL | |
DMSO | 20 mM | 0.1411 mL | 0.7053 mL | 1.4106 mL | 3.5266 mL |
50 mM | 0.0564 mL | 0.2821 mL | 0.5643 mL | 1.4106 mL | |
100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Seliciclib 186692-46-6 Cell Cycle/Checkpoint CDK Roscovitine CYC-202 inhibit CYC 202 Inhibitor R-roscovitine CYC202 Cyclin dependent kinase inhibitor